The goal of this post-market clinical follow up Study is to demonstrate the efficacy, safety, acceptability, and quality of life implications of Essilor® Stellest® spectacle lenses in slowing myopia progression in European children and adolescents. Participants will receive Essilor® Stellest® at inclusion visit and will be asked for a full time wear (\>12 hours daily) for 24 months. The primary endpoints are the change in axial length and cycloplegic autorefraction from baseline to 24 months compared to expected change based on axial length and refraction centile positions at baseline.
Protocol Amendment History
6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-02-14; most recent amendment 2025-11-27.
Status change: Recruiting → Active, Not Recruiting2025-08-11
Status change: Not Yet Recruiting → Recruiting2024-04-02